Not all neoantigens are created equal
Drug Target Review
DECEMBER 28, 2023
In most cancers, the tumour evolves by acquiring mutations that confer growth advantages or resistance to therapies. Recent advances in bioinformatics show clonal neoantigens are the best targets for immunotherapy, as I will elucidate below. This allows the cancer to evolve and develop resistance to the therapy.
Let's personalize your content